mirtazapine has been researched along with Autism Spectrum Disorder in 2 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Autism Spectrum Disorder: Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was a 10-week double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in youth with autism spectrum disorder (ASD)." | 9.51 | A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. ( Erickson, CA; Keary, CJ; Mathieu-Frasier, L; McDougle, CJ; Mullett, JE; Palumbo, ML; Politte, LC; Posey, DJ; Ravichandran, CT; Stigler, KA; Thom, RP, 2022) |
| "This study was a 10-week double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in youth with autism spectrum disorder (ASD)." | 5.51 | A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. ( Erickson, CA; Keary, CJ; Mathieu-Frasier, L; McDougle, CJ; Mullett, JE; Palumbo, ML; Politte, LC; Posey, DJ; Ravichandran, CT; Stigler, KA; Thom, RP, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| McDougle, CJ | 1 |
| Thom, RP | 1 |
| Ravichandran, CT | 1 |
| Palumbo, ML | 1 |
| Politte, LC | 1 |
| Mullett, JE | 1 |
| Keary, CJ | 1 |
| Erickson, CA | 1 |
| Stigler, KA | 1 |
| Mathieu-Frasier, L | 1 |
| Posey, DJ | 1 |
| Akbas, B | 1 |
| Akca, OF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders[NCT01302964] | Phase 3 | 30 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Pediatric Anxiety Rating Scale (PARS) is a clinician-rated instrument that assesses anxiety symptoms that are commonly associated with social anxiety, separation anxiety, and generalized anxiety disorders. Scaled score ranges form 0-25 with higher scores indicating more severe anxiety symptoms. Means were estimated using a repeated measures linear regression model with treatment group, study week (in categories), and their interaction as covariates, and assuming a common mean between treatment groups at baseline. Confidence intervals reflect a Bonferroni multiple testing correction accounting for the selection of two primary outcomes. (NCT01302964)
Timeframe: Weeks Baseline, 2, 4, 6, and 10
| Intervention | score on a scale (Mean) |
|---|---|
| Mirtazapine | -4.9 |
| Placebo | -3.2 |
The Clinical Global Impressions Global Improvement (CGI-I) is designed to take into account all factors to arrive at an assessment of response to treatment. The CGI-I scale ranges from 1 to 7 (1=very much improved; 2= much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse), with lower scores indicating improvement (1=very much improved and 2=much improved). In this study the CGI was focused on the target symptom of anxiety. Participants with a CGI-I score of 1 or 2 were classified as responders. The CGI-I was administered biweekly for 6 weeks and again at 10 weeks during the study. The participant who withdrew from the study before 10 weeks was not included in the calculations. (NCT01302964)
Timeframe: Screen (Visit 1) Baseline (Visit 2) and Endpoint (Week 10)
| Intervention | Proportion of participants (Number) |
|---|---|
| Mirtazapine | 0.47 |
| Placebo | 0.20 |
1 trial available for mirtazapine and Autism Spectrum Disorder
| Article | Year |
|---|---|
A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder.
Topics: Adolescent; Anxiety; Anxiety Disorders; Autism Spectrum Disorder; Child; Child, Preschool; Double-Bl | 2022 |
1 other study available for mirtazapine and Autism Spectrum Disorder
| Article | Year |
|---|---|
Treatment of a Child with Autism Spectrum Disorder and Food Refusal Due to Restricted and Repetitive Behaviors.
Topics: Aggression; Aripiprazole; Autism Spectrum Disorder; Child; Feeding and Eating Disorders; Humans; Mal | 2018 |